CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company, announced today the first patient enrollment in its US pivotal study (HOPE), designed to demonstrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results